NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

💉 Vaccines

Location

Netherlands

Market Cap

USD 2.02 B

Share Price

USD 17.96

Avg Daily Volume

921,979

Change (1 day)

-1.32%

Change (1 year)

4.24%

Change (YTD)

-30.12%

NewAmsterdam Pharma Company N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD -255.78 M

NewAmsterdam Pharma Company N.V. EBITDA is USD -255.78 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 36.77% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

NewAmsterdam Pharma Company N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -187.01 M, a 163.94% change year over year.
NewAmsterdam Pharma Company N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -70.85 M, a -6,779.58% change year over year.
NewAmsterdam Pharma Company N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 1.06 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	68
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals 💉 Vaccines

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.